ArticleOncotarget2018
Immunotherapy in mucosal melanoma: a case report and review of the literature.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Mucosal Melanoma of the Oral Cavity: Prognostic Factors Influencing Patient Survival Outcomes.Journal of clinical medicine · 2025Review
- Anorectal mucosal melanoma.Seminars in colon & rectal surgery · 2023Article
- Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.Current oncology reports · 2023Review
- Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?Diseases of the colon and rectum · 2021Article
- Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.Frontiers in immunology · 2021Review
- Article
- Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.The Journal of pathology · 2019Review
- Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.Cancer biology & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal melanoma is a rare form of melanoma presenting variably as sores or unexplained bleeding located mainly in the head and neck region, anorectal region or female genital tract. Mucosal melanoma is usually diagnosed at an advanced stage and is characterized by an aggressive behavior. Surgery represents the mainstay of treatment for early stage melanomas, but for advanced disease there have been until recently very limited treatment options. Ipilimumab, a human monoclonal antibody directed against the cytotoxic T lymphocyte antigen 4, was the first treatment modality to demonstrate survival benefit in advanced malignant melanoma.
methodDescription of a new case and review of the literature.
resultsWe present here a patient with mucosal melanoma with aggressive biological behavior and documented late response to ipilimumab.
conclusionsIpilimumab represents an effective treatment option in selected patients with mucosal melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.